|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pécuchet N, Zonta E, Didelot A, Combe P,
Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig
P, et al: Base-position error rate analysis of next-generation
sequencing applied to circulating tumor DNA in non-small cell lung
cancer: A prospective study. PLoS Med. 13:e10021992016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li
DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218
contributes to epithelial-mesenchymal transition and tumor
metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reka AK, Chen G, Jones RC, Amunugama R,
Kim S, Karnovsky A, Standiford TJ, Beer DG, Omenn GS and Keshamouni
VG: Epithelial-mesenchymal transition-associated secretory
phenotype predicts survival in lung cancer patients.
Carcinogenesis. 35:1292–1300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frick MA, Kao GD, Aguarin L, Chinniah C,
Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C,
Hahn SM, et al: Circulating tumor cell assessment in presumed early
stage non-small cell lung cancer patients treated with stereotactic
body radiation therapy: A prospective pilot study. Int J Radiat
Oncol Biol Phys. 102:536–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morbelli S, Alama A, Ferrarazzo G, Coco S,
Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta
G, et al: Circulating tumor DNA reflects tumor metabolism rather
than tumor burden in chemotherapy-naive patients with advanced
non-small cell lung cancer: 18F-FDG PET/CT study. J Nucl
Med. 58:1764–1769. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanssen A, Loges S, Pantel K and Wikman H:
Detection of circulating tumor cells in non-small cell lung cancer.
Front Oncol. 5:2072015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yao D, Dai C and Peng S: Mechanism of the
mesenchymal-epithelial transition and its relationship with
metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang S, Wu T, Peng X, Liu J, Liu F, Wu S,
Liu S, Dong Y, Xie S and Ma S: Mesenchymal phenotype of circulating
tumor cells is associated with distant metastasis in breast cancer
patients. Cancer Manag Res. 9:691–700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalluri R: EMT: When epithelial cells
decide to become mesenchymal-like cells. J Clin Invest.
119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8. Cham
Switzerland: Springer; 2017
|
|
18
|
Wu S, Liu S, Liu Z, Huang J, Pu X, Li J,
Yang D, Deng H, Yang N and Xu J: Classification of circulating
tumor cells by epithelial-mesenchymal transition markers. PLoS One.
10:e01239762015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fluss R, Faraggi D and Reiser B:
Estimation of the youden index and its associated cutoff point.
Biom J. 47:458–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kraljevic Pavelic S, Sedic M, Bosnjak H,
Spaventi S and Pavelic K: Metastasis: New perspectives on an old
problem. Mol Cancer. 10:222011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin Y, Li F, Zheng C, Wang Y, Fang Z, Guo
C, Wang X, Liu H, Deng L, Li C, et al: NEDD9 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Int J Cancer.
134:2294–2304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oakman C, Pestrin M, Bessi S, Galardi F
and Di Leo A: Significance of micrometastases: Circulating tumor
cells and disseminated tumor cells in early breast cancer. Cancers
(Basel). 2:1221–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonnomet A, Brysse A, Tachsidis A, Waltham
M, Thompson EW, Polette M and Gilles C: Epithelial-to-mesenchymal
transitions and circulating tumor cells. J Mammary Gland Biol
Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nauseef JT and Henry MD:
Epithelial-to-mesenchymal transition in prostate cancer: Paradigm
or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Busch EL, Keku TO, Richardson DB, Cohen
SM, Eberhard DA, Avery CL and Sandler RS: Evaluating markers of
epithelial-mesenchymal transition to identify cancer patients at
risk for metastatic disease. Clin Exp Metastasis. 33:53–62. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan TZ, Miow QH, Miki Y, Noda T, Mori S,
Huang RY and Thiery JP: Epithelial-mesenchymal transition spectrum
quantification and its efficacy in deciphering survival and drug
responses of cancer patients. EMBO Mol Med. 6:1279–1293. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raimondi C, Nicolazzo C and Gradilone A:
Circulating tumor cells isolation: The ‘post-EpCAM era’. Chin J
Cancer Res. 27:461–470. 2015.PubMed/NCBI
|
|
29
|
Ferreira MM, Ramani VC and Jeffrey SS:
Circulating tumor cell technologies. Mol Oncol. 10:374–394. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lowes LE and Allan AL: Circulating tumor
cells and implications of the epithelial-to-mesenchymal transition.
Adv Clin Chem. 83:121–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Saad S, Al-Shibli K, Donnem T, Persson
M, Bremnes RM and Busund LT: The prognostic impact of NF-kappaB
p105, vimentin, E-cadherin and Par6 expression in epithelial and
stromal compartment in non-small-cell lung cancer. Br J Cancer.
99:1476–1483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dauphin M, Barbe C, Lemaire S,
Nawrocki-Raby B, Lagonotte E, Delepine G, Birembaut P, Gilles C and
Polette M: Vimentin expression predicts the occurrence of
metastases in non small cell lung carcinomas. Lung Cancer.
81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pallier K, Cessot A, Côté JF, Just PA,
Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M,
Ansieau S, et al: TWIST1 a new determinant of epithelial to
mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS
One. 7:e299542012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hui L, Zhang S, Dong X, Tian D, Cui Z and
Qiu X: Prognostic significance of twist and N-cadherin expression
in NSCLC. PLoS One. 8:e621712013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mirza S, Jain N and Rawal R: Evidence for
circulating cancer stem-like cells and epithelial-mesenchymal
transition phenotype in the pleurospheres derived from lung
adenocarcinoma using liquid biopsy. Tumour Biol.
39:10104283176959152017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Milano A, Mazzetta F, Valente S, Ranieri
D, Leone L, Botticelli A, Onesti CE, Lauro S, Raffa S, Torrisi MR
and Marchetti P: Molecular detection of EMT markers in circulating
tumor cells from metastatic non-small cell lung cancer patients:
Potential role in clinical practice. Anal Cell Pathol (Amst).
2018:35068742018.PubMed/NCBI
|
|
37
|
Houthuijzen JM, Daenen LG, Roodhart JM and
Voest EE: The role of mesenchymal stem cells in anti-cancer drug
resistance and tumour progression. Br J Cancer. 106:1901–1906.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kitamura T, Qian BZ and Pollard JW: Immune
cell promotion of metastasis. Nat Rev Immunol. 15:73–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tripathi SC, Peters HL, Taguchi A,
Katayama H, Wang H, Momin A, Jolly MK, Celiktas M,
Rodriguez-Canales J, Liu H, et al: Immunoproteasome deficiency is a
feature of non-small cell lung cancer with a mesenchymal phenotype
and is associated with a poor outcome. Proc Natl Acad Sci USA.
113:E1555–E1564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lowes LE, Lock M, Rodrigues G, D'Souza D,
Bauman G, Ahmad B, Venkatesan V, Allan AL and Sexton T: The
significance of circulating tumor cells in prostate cancer patients
undergoing adjuvant or salvage radiation therapy. Prostate Cancer
Prostatic Dis. 18:358–364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lucci A, Hall CS, Lodhi AK, Bhattacharyya
A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM and Krishnamurthy S:
Circulating tumour cells in non-metastatic breast cancer: A
prospective study. Lancet Oncol. 13:688–695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lowes LE, Lock M, Rodrigues G, D'Souza D,
Bauman G, Ahmad B, Venkatesan V, Allan AL and Sexton T: Circulating
tumour cells in prostate cancer patients receiving salvage
radiotherapy. Clin Transl Oncol. 14:150–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meyer CP, Pantel K, Tennstedt P, Stroelin
P, Schlomm T, Heinzer H, Riethdorf S and Steuber T: Limited
prognostic value of preoperative circulating tumor cells for early
biochemical recurrence in patients with localized prostate cancer.
Urol Oncol. 34:235.e11–e16. 2016. View Article : Google Scholar
|
|
44
|
Chen X, Zhou F, Li X, et al: Folate
Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based
Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer. J
Thorac Oncol. 10:1163–1171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Franken B, de Groot MR, Mastboom WJ,
Vermes I, van der Palen J, Tibbe AG and Terstappen LW: Circulating
tumor cells, disease recurrence and survival in newly diagnosed
breast cancer. Breast Cancer Res. 14:R1332012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kasimir-Bauer S, Hoffmann O, Wallwiener D,
Kimmig R and Fehm T: Expression of stem cell and
epithelial-mesenchymal transition markers in primary breast cancer
patients with circulating tumor cells. Breast Cancer Res.
14:R152012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yokobori T, Iinuma H, Shimamura T, Imoto
S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, et
al: Plastin3 is a novel marker for circulating tumor cells
undergoing the epithelial-mesenchymal transition and is associated
with colorectal cancer prognosis. Cancer Res. 73:2059–2069. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun YF, Guo W, Xu Y, Shi YH, Gong ZJ, Ji
Y, Du M, Zhang X, Hu B, Huang A, et al: Circulating tumor cells
from different vascular sites exhibit spatial heterogeneity in
epithelial and mesenchymal composition and distinct clinical
significance in hepatocellular carcinoma. Clin Cancer Res.
24:547–559. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Willipinski-Stapelfeldt B, Riethdorf S,
Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J and Pantel K:
Changes in cytoskeletal protein composition indicative of an
epithelial-mesenchymal transition in human micrometastatic and
primary breast carcinoma cells. Clin Cancer Res. 11:8006–8014.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim MY, Oskarsson T, Acharyya S, Nguyen
DX, Zhang XH, Norton L and Massagué J: Tumor self-seeding by
circulating cancer cells. Cell. 139:1315–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chao Y, Wu Q, Shepard C and Wells A:
Hepatocyte induced re-expression of E-cadherin in breast and
prostate cancer cells increases chemoresistance. Clin Exp
Metastasis. 29:39–50. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gao D, Joshi N, Choi H, Ryu S, Hahn M,
Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, et al: Myeloid
progenitor cells in the premetastatic lung promote metastases by
inducing mesenchymal to epithelial transition. Cancer Res.
72:1384–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|
